"MW explained to MM [that is Mr. Wagner explained to Mr. Murray Mackay] that BASF have made the commercial decision not to deliver to Zantra in 2016. MW apologised and explained that he was aware of the impact this might have on MM's business but had no choice due to the commercial impact it would have on BASF ... "
"JT explained to Zantra that the decision not to supply them had been made just before the telephone call between BASF and Zantra on Friday12th December 2015 . BASF had started on the path to setting up an account with Zantra, but had reviewed the commercial impact of the decision and decided not to proceed with supplying them in 2016. MM questioned whether the response from the national distributors had been so substantial that the value of the business BASF would lose as a result of the distributor's reaction overrode the value the business that Zantra could produce for BASF. JT explained that the decision had been made in the best business interests of BASF. The reaction from the market had been far in excess of what had been expected ... "
"CW said that it was clear that BASF had come under significant pressure from their distributors, which was a breach of competition law. We would like BASF to delay the announcement and think about ways to supply Zantra and not upset the other distributors at the same time."
"MM agreed that the communication would be very detrimental to Zantra as it would reflect very badly on them and would prevent them from attracting other large manufacturers. MM believes that it is very clear that the reason behind BASF's decision is that BASF has succumbed to market pressure and this was clearly unacceptable behaviour from their competitors as they are trying to stop a new entrant from entering into the crop protection market. MM asked BASF to reconsider their decision not to supply Zantra and to not communicate their decision to the market as the last thing he wants is to be in conflict with BASF."
"The events which took place following the announcement are summarised below. (i) After the announcement was made there was discussions between BASF and some of its distributors. (ii) It became clear to BASF that the appointment of Zantra as the distributor would cause significant unrest amongst its distributors and that was going to result in a significant reduction in the orders received from them. (iii) None of the distributors asked BASF not to appoint Zantra as a distributor. (iv) One of distributors mentioned a specific issue which it had with Zantra's appointment. It had been involved in a separate legal dispute with Zantra. The distributor claimed that this dispute had highlighted concerns regarding the way in which Zantra did business. "
“The three conditions to be satisfied for the court to exercise the power to order Norwich Pharmacal relief are: i) a wrong must have been carried out, or arguably carried out, by an ultimate wrongdoer; ii) there must be the need for an order to enable action to be brought against the ultimate wrongdoer; and iii) the person against whom the order is sought must: (a) be mixed up in so as to have facilitated the wrongdoing; and (b) be able or likely to be able to provide the information necessary to enable the ultimate wrongdoer to be sued.”
"I do not know how Murray has gained the impression that the national distributors (or indeed any BASF distributors) have acted in concert or that there has been any threat of a collective boycott."
“The origin of the jurisdiction is the statement of principle contained in the speech of Lord Reid in Norwich Pharmacal Co v. CEC[1974] AC 133 at 175. However the key qualification in relation to the jurisdiction was set out by Lord Reid at 174 in these terms: "It is not available against a person who has no other connection with the wrong than that he was a spectator or has some document relating to it in his possession". The reason why the respondent in those proceedings was treated differently was because "… without certain action on their part the infringements could never have been committed". It was these qualifications that led Lord Reid to formulate the principle that the claimants seek to rely on in this case in these terms: " … if through no fault of his own, a person gets mixed up in the tortious acts of others so as to facilitate their wrong doing he may incur no personal liability but comes under a duty to assist the person who has been wronged by giving him full information …" However, as Lord Reid said in Norwich Pharmacal, "… information cannot be obtained by discovery from a person who will in due course be compellable to give that information … on a subpoena duces tecum…". Hence the remedy, which is an exceptional procedural device made available to avoid injustice, is available only against those who won't, or are unlikely to, be liable for the wrong but have nevertheless become mixed up in its commission. Outside that limited class the remedy is not available.”
“i). The strength of the possible cause of action identified by the applicant for the order; ii) The strong public interest in allowing an applicant to vindicate his legal rights; iii) Whether making an order will deter similar wrong doing in the future; iv) Whether information could be obtained from another source; v) Whether the respondent was aware or ought to have known that he was facilitating arguable wrong doing; and vi) The degree to which the material sought is confidential.”